A. Røssevold

Atezolizumab plus anthracycline-based chemotherapy in metastatic triple-negative breast cancer: the randomized, double-blind phase 2b ALICE trial

H. Russnes, B. Naume, Ø. Garred, 2022, Nature Medicine.

ALICE: a randomized placebo-controlled phase II study evaluating atezolizumab combined with immunogenic chemotherapy in patients with metastatic triple-negative breast cancer

B. Naume, J. Kyte, R. Falk, 2020, Journal of Translational Medicine.

An independent poor-prognosis subtype of breast cancer defined by a distinct tumor immune microenvironment

Tonje G. Lien, A. Frigessi, T. Sørlie, 2019, Nature Communications.

ALICE: a randomized placebo-controlled phase II study evaluating atezolizumab combined with immunogenic chemotherapy in patients with metastatic triple-negative breast cancer

J. Kyte, R. Falk, A. Røssevold, 2020, Journal of Translational Medicine.